Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens

项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染

基本信息

项目摘要

ABSTRACT Leveraging Metagenomics of the Microbiome to Predict Colonization/Infection by Antimicrobial- Resistant Pathogens (Project #2) Antimicrobial resistance is a growing, global threat to public health. Vancomycin-resistant enterococci (VRE), extended spectrum β-lactamase producing/carbapenem-resistant Enterobacteriaceae (ESBL-E/CRE) and Clostridiodes difficile are key antimicrobial resistant (AMR) pathogens that share the intestine as the initial site of colonization. Therefore, colonization resistance provided by the commensal microbiota of the intestines is a critical aspect of the pathophysiology of these organisms. The completion of the initial stages of the Human Microbiome Project has provided new understanding of how the microbiome impacts infections and has generated novel tools for further advances in this critical area of human health. Additionally, unbiased approaches to bacterial identification have resulted in increasing appreciation that VRE, ESBL-E/CRE, and C. difficile often co-colonize patients suggesting that these organisms are interacting with each other in addition to the commensal microflora. The long term goals of this project, in synergy with other portions of this P01 proposal, are to dissect the mechanisms underlying how interactions among the commensal microflora, the host, and VRE, ESBL-E/CRE, and C. difficile impact intestinal colonization and subsequent infection by these AMR pathogens. Although it is well known that microbiome disruption by antimicrobials is a key initial step in colonization by these pathogens, we seek to address the key knowledge gap of why only a subset of patients receiving antimicrobials become colonized and eventually infected by these organisms. To this end, we propose performing longitudinal studies of intensive care unit and hematopoietic stem cell transplant patients at two distinct hospitals in the Texas Medical Center. Patients will be classified depending on both initial and longitudinal colonization status, and these classifications will be correlated with metagenomics based microbiome analyses of serial stool samples. In concert with computational biologists, the metagenomics data will be mined for particularly species or combinations of species that are either protective against or positively associated with colonization and infection, including co-colonization. Additionally, we will test whether samples from the clinical cohort can protect mice from AMR pathogen challenge to validate associations observed clinically. Finally, we will also use animal models to test how pre-existing colonization with a particular organism under study impacts subsequent colonization by a distinct AMR pathogen. By synergizing with microbiota experts, computational biologists, and physician-scientists from the highly integrated Gulf Coast Consortium on Antimicrobial Resistance, this proposal seeks to sharpen understanding of how critical AMR pathogens colonize and infect humans in order to provide a critical platform for novel preventive or therapeutic approaches to mitigate the AMR scourge.
抽象的 利用微生物组的宏基因组学来预测抗菌药物的定植/感染 耐药病原体(项目#2) 抗生素耐药性是对公共健康日益严重的全球威胁。耐万古霉素肠球菌(VRE), 产生超广谱 β-内酰胺酶/耐碳青霉烯类肠杆菌 (ESBL-E/CRE) 和 艰难梭菌是关键的抗菌素耐药 (AMR) 病原体,其起始部位为肠道 殖民化。因此,肠道共生微生物群提供的定植抗性是 这些生物体病理生理学的关键方面。人类初级阶段的完成 微生物组项目提供了对微生物组如何影响感染的新认识,并已 产生了新的工具,以进一步推动人类​​健康这一关键领域的发展。另外,不偏不倚 细菌鉴定方法使人们越来越认识到 VRE、ESBL-E/CRE 和 C. 艰难梭菌经常在患者中共同定殖,这表明这些微生物除了 共生微生物区系。该项目的长期目标与 P01 提案的其他部分相协同, 目的是剖析共生微生物群、宿主和万能抗微生物药物之间相互作用的潜在机制, ESBL-E/CRE 和艰难梭菌会影响这些 AMR 病原体的肠道定植和随后的感染。 尽管众所周知,抗菌药物对微生物组的破坏是这些细菌定植的关键初始步骤 病原体,我们寻求解决关键知识差距,即为什么只有一小部分患者接受抗菌药物 被这些生物定植并最终感染。为此,我们建议进行纵向 对德克萨斯州两家不同医院的重症监护室和造血干细胞移植患者的研究 医疗中心。将根据初始和纵向定植状态对患者进行分类,并且 这些分类将与基于宏基因组学的连续粪便样本微生物组分析相关。 与计算生物学家合作,将挖掘特定物种或特定物种的宏基因组数据。 对定植和感染具有保护作用或与定植和感染呈正相关的物种组合, 包括共同殖民。此外,我们将测试临床队列中的样本是否可以保护小鼠 从 AMR 病原体挑战中验证临床观察到的关联。最后,我们还将使用动物 测试所研究的特定生物体先前存在的定植如何影响后续的模型 一种独特的 AMR 病原体定植。通过与微生物群专家、计算生物学家和 来自高度一体化的墨西哥湾沿岸抗菌素耐药性联盟的医生科学家,该提案 旨在加深对关键 AMR 病原体如何定植和感染人类的​​了解,以便提供 一个重要的平台,用于减轻抗菌素耐药性祸害的新型预防或治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL A SHELBURNE其他文献

SAMUEL A SHELBURNE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL A SHELBURNE', 18)}}的其他基金

Role of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant Enterobacteriaceae
β-内酰胺酶编码基因扩增在产生非碳青霉烯酶、耐碳青霉烯肠杆菌科细菌中的作用
  • 批准号:
    10373951
  • 财政年份:
    2021
  • 资助金额:
    $ 54.31万
  • 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
  • 批准号:
    10301505
  • 财政年份:
    2021
  • 资助金额:
    $ 54.31万
  • 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
  • 批准号:
    10449272
  • 财政年份:
    2021
  • 资助金额:
    $ 54.31万
  • 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
  • 批准号:
    10226288
  • 财政年份:
    2020
  • 资助金额:
    $ 54.31万
  • 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
  • 批准号:
    10024960
  • 财政年份:
    2020
  • 资助金额:
    $ 54.31万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8300803
  • 财政年份:
    2011
  • 资助金额:
    $ 54.31万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8107818
  • 财政年份:
    2011
  • 资助金额:
    $ 54.31万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8479310
  • 财政年份:
    2011
  • 资助金额:
    $ 54.31万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8692634
  • 财政年份:
    2011
  • 资助金额:
    $ 54.31万
  • 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
  • 批准号:
    8871663
  • 财政年份:
    2011
  • 资助金额:
    $ 54.31万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 54.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了